LinkedIn
WebsiteMETSERA INC: Clinical-Stage Biotech Targeting Obesity
METSERA INC (NASDAQ: MTSR) is a clinical-stage biotechnology company headquartered in New York City. Its mission is to address the physical, emotional, and economic burdens of obesity by developing ultra-long acting, nutrient-stimulated hormone (NuSH) therapies. The company employs an integrated approach that includes peptide engineering, translational science, clinical development, and large-scale manufacturing.
Corporate Structure and Team
Founded in 2022 by Population Health Partners and ARCH Venture Partners, Metsera has raised approximately $290 million in financing from healthcare investors. The organization employs between 11 and 50 professionals, including experienced company builders and drug developers, who advance a portfolio of injectable and oral therapeutic candidates designed to improve potency, durability, combinability, and scalability.
Obesity treatment by i yunmai
Developments and News
In October 2024, Health Canada approved a Clinical Trial Application for MET-002o, a prototype oral peptide, initiating a formulation optimization trial under the MOMENTUM™ delivery platform.
From June 20–23, 2025, Metsera presented updated clinical and preclinical findings at the 85th ADA SciSessions in Chicago, which included progress on its lead GLP-1 receptor agonist, MET-097i.
On July 28, 2025, the company filed its Form 10-Q for the quarter ended June 30, 2025, and submitted an 8-K current report covering Items 2.02 and 9.01.
On September 3 and 4, 2025, CEO Whit Bernard presented at the Cantor Global Healthcare Conference and the Wells Fargo Healthcare Conference, respectively, providing updates on pipeline milestones and strategic priorities.
From September 15–19, 2025, Metsera will present data from its next-generation NuSH therapies, including an initial efficacy readout for its monthly amylin analog MET-233i, at EASD 2025 in Vienna.
Financial and Strategic Analysis
| Metric | Value |
|---|---|
| Share Price (9/22) | $53.88 |
| Change | +61.70% |
| Volume | 1,407,953 |
| Exchange | NASDAQ (MTSR) |
Since its Nasdaq listing, Metsera’s stock has shown notable volatility. The 61.70 percent gain on September 22, 2025, reflects increased investor interest ahead of key clinical readouts. The company’s focus on NuSH therapies aims to address limitations of existing treatments, such as the frequency of injections and tolerability issues, by developing both injectable and oral formulations intended for once-monthly dosing. With multiple candidates in IND-enabling and clinical stages, Metsera seeks to achieve FDA approvals under the biologics license application (BLA) pathway.
Market Position and Industry Context
Obesity treatment continues to evolve, with demand for scalable, patient-friendly therapies. Metsera operates in a competitive landscape that includes established GLP-1 receptor agonists and emerging oral peptide developers. Its dual-modality pipeline and lipidation platforms aim to differentiate on convenience and cost-efficiency. Partnerships with regulatory bodies, presentations at scientific conferences, and ongoing clinical milestones position the company to capture a share of the growing market for metabolic disease therapeutics.
TL;DR
- On September 22, 2025, shares of Metsera closed at $53.88, up 61.70% on a volume of 1,407,953.
- A Clinical Trial Application for MET-002o was approved by Health Canada in October 2024; dosing is underway.
- Phase 1 data for MET-233i and upcoming Phase 2b VESPER-1 and interim VESPER-3 assessments are expected throughout September 2025.
- A global Phase 3 initiation of MET-097i is planned for late 2025.
- Scientific presentations are scheduled for September 15–19, 2025, at EASD 2025 in Vienna, where further efficacy and safety findings will be shared.
